| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MMAE |
| Uniprot No | B2HKM3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-289aa |
| 氨基酸序列 | MTLNVKGEGLGAQITGVDPKNLDDITTDEIRDIVYANKLVILKDVNPSPEEFLKLGKIVGQIVPYYEPMYHHEDHPEIFVSSTEEGQGVPKTGAFWHIDYMFMPEPFAFSMVLPLAVPGHDRGTYFIDLAKVWQSLPAAQQAPARGTLSTHDPRRHIKIRPSDVYRPIGEVWDEISRATPPIKWPTVIRHPKTGEEILYICATGTTKIEDKDGNLVDPAVLAELLAATGQLDPEYNSPFIHTQHYEVGDIILWDNRVLMHRAKHGTASGTLTTYRLTMLDGLETPGYPA |
| 预测分子量 | 32,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MMAE(单甲基澳瑞他汀E)重组蛋白的参考文献示例(内容基于学术文献结构概括，非真实引用)：
1. **文献名称**: *Antibody-Drug Conjugates with Monomethyl Auristatin E for Targeted Cancer Therapy*
**作者**: Doronina, S.O. et al.
**摘要**: 研究报道了MMAE作为微管抑制剂在抗体药物偶联物(ADC)中的应用，通过重组抗体靶向递送MMAE至肿瘤细胞，显著提高抗癌活性并降低系统性毒性。
2. **文献名称**: *Engineering Recombinant Antibody-MMAE Conjugates for Enhanced Stability and Potency*
**作者**: Beck, A. et al.
**摘要**: 探讨了重组抗体与MMAE的化学偶联技术优化，通过引入定点偶联策略改善ADC的稳定性和药效，并在多种肿瘤模型中验证其疗效。
3. **文献名称**: *In Vitro and In Vivo Activity of MMAE-Based Recombinant Protein Therapeutics*
**作者**: Peters, C. & Brown, R.
**摘要**: 评估了含MMAE的重组蛋白药物的体外细胞毒性和体内抗肿瘤效果，证明其通过靶向降解微管蛋白抑制肿瘤增殖，并具有剂量依赖性疗效。
4. **文献名称**: *Pharmacokinetic Analysis of MMAE-Conjugated Recombinant Antibodies in Preclinical Models*
**作者**: Kumar, R. et al.
**摘要**: 分析了MMAE重组蛋白偶联物的药代动力学特性，揭示其较长的半衰期和肿瘤组织特异性蓄积能力，为临床剂量设计提供依据。
---
注：以上为示例性内容，实际文献需通过PubMed、Web of Science等数据库检索关键词如“MMAE recombinant protein”“ADC MMAE”获取。经典研究多集中于《Nature Biotechnology》《Cancer Research》等期刊。
**Background of MMAE Recombinant Proteins**
Monomethyl auristatin E (MMAE) is a potent synthetic antineoplastic agent derived from dolastatin 10. a natural cytostatic peptide isolated from marine sea hare *Dolabella auricularia*. As a microtubule-disrupting payload, MMAE inhibits cell division by binding to tubulin, preventing polymerization, and inducing apoptosis in rapidly dividing cells. Its high cytotoxicity, however, limits standalone therapeutic use due to off-target effects.
To harness MMAE’s potency while minimizing systemic toxicity, recombinant protein technologies have enabled its integration into targeted therapies, particularly antibody-drug conjugates (ADCs). In ADCs, MMAE is covalently linked to monoclonal antibodies (mAbs) via cleavable or non-cleavable linkers. These antibodies specifically recognize tumor-associated antigens, delivering MMAE directly to cancer cells. For example, MMAE-based ADCs like brentuximab vedotin (targeting CD30) and polatuzumab vedotin (targeting CD79b) are clinically approved for lymphoma treatments.
Recombinant production of MMAE-conjugated proteins involves genetic engineering of host cells (e.g., CHO or *E. coli*) to express antibody-linker complexes, followed by chemical conjugation to MMAE. Advances in site-specific conjugation techniques (e.g., engineered cysteine residues or enzymatic tagging) have improved ADC homogeneity and efficacy.
Beyond ADCs, MMAE recombinant proteins are explored in bispecific antibodies, immunotoxins, and prodrug systems to enhance tumor selectivity. Challenges remain, including optimizing linker stability, reducing immunogenicity, and overcoming drug resistance. Nonetheless, MMAE-based recombinant proteins represent a cornerstone in precision oncology, balancing potent cytotoxicity with targeted delivery to improve therapeutic outcomes.
×
